24 HR phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule — RxCUI 1313059
RxNorm drug concept · Semantic clinical drug
RxCUI 1313059
Semantic clinical drug · SCD
● Current RxNorm concept 16 FDA products
17 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1313059
Official name24 HR phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asphentermine 11.25 MG / topiramate 69 MG 24HR Extended Release Oral Capsule
FDA products mapped16
Package NDCs mapped17
Reported Medicaid activity (SDUD)914 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Phentermine and Topiramate: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's more than a simple appetite suppressant. Phentermine and topiramate combines two different drugs: phentermine reduces your appetite by triggering certain brain chemicals, and...
- What exactly does this medication do — is it just a diet pill?
- Take it once every morning — timing really does matter here. Taking it in the evening can interfere with your sleep. The good news is you can take it with or without food, so don't...
- When should I take it, and does it matter if I eat first?
🕸️ Concept Web — How 24 HR phentermine 11.25 MG / topiramate 69 MG Ex... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
24 HR phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule
RxCUI 1313059 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Phentermine
8152IN -
Topiramate
38404IN -
Phentermine / topiramate
1302826MIN
-
Phentermine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Qsymia
1372703BN
-
Qsymia
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Phentermine / topiramate Extended Release Oral Capsule
1302825SCDF -
Phentermine / topiramate Oral Product
1302823SCDG -
Phentermine / topiramate Pill
1302824SCDG -
Phentermine / topiramate Extended Release Oral Capsule [Qsymia]
1302830SBDF -
Qsymia Oral Product
1302831SBDG -
Qsymia Pill
1302832SBDG -
Extended Release Oral Capsule
316943DF -
Oral Product
1151131DFG - +1 more in this family
-
Phentermine / topiramate Extended Release Oral Capsule
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Phentermine 11.25 MG
1313058SCDC -
Topiramate 69 MG
1302860SCDC -
24 HR phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule [Qsymia]
1313061SBD -
Phentermine 11.25 MG / topiramate 69 MG [Qsymia]
1313060SBDC
-
Phentermine 11.25 MG
Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Phentermine 11.25 MG
SCDC · 1313058 -
Topiramate 69 MG
SCDC · 1302860 -
Phentermine / topiramate Extended Release Oral Capsule
SCDF · 1302825 -
Phentermine / topiramate Oral Product
SCDG · 1302823 -
Phentermine / topiramate Pill
SCDG · 1302824
Brand-Name Concepts
-
24 HR phentermine 11.25 MG / topiramate 69 MG Extended Release Oral Capsule [Qsymia]
SBD · 1313061 -
Phentermine 11.25 MG / topiramate 69 MG [Qsymia]
SBDC · 1313060 -
Phentermine / topiramate Extended Release Oral Capsule [Qsymia]
SBDF · 1302830 -
Qsymia Oral Product
SBDG · 1302831 -
Qsymia Pill
SBDG · 1302832 -
Qsymia
BN · 1372703
📦 FDA Products & Package NDCs
16 products · 17 package NDCs
17 package NDCs map to RxCUI 1313059 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00480-2299-56 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0480-2299-56) | Phentermine and topiramate | Teva Pharmaceuticals, Inc. | 2025-05-07 |
| 00480-3295-56 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0480-3295-56) | Phentermine and topiramate | Teva Pharmaceuticals, Inc. | 2025-05-07 |
| 00480-3296-56 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0480-3296-56) | Phentermine and topiramate | Teva Pharmaceuticals, Inc. | 2025-05-07 |
| 00480-3297-56 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0480-3297-56) | Phentermine and topiramate | Teva Pharmaceuticals, Inc. | 2025-05-07 |
| 43598-0624-30 | 30 CAPSULE in 1 BOTTLE (43598-624-30) | Phentermine and Topiramate Extended-Release | Dr.Reddys Laboratories Inc | 2025-06-12 |
| 43598-0625-30 | 30 CAPSULE in 1 BOTTLE (43598-625-30) | Phentermine and Topiramate Extended-Release | Dr.Reddys Laboratories Inc | 2025-06-12 |
| 43598-0626-30 | 30 CAPSULE in 1 BOTTLE (43598-626-30) | Phentermine and Topiramate Extended-Release | Dr.Reddys Laboratories Inc | 2025-06-12 |
| 43598-0627-30 | 30 CAPSULE in 1 BOTTLE (43598-627-30) | Phentermine and Topiramate Extended-Release | Dr.Reddys Laboratories Inc | 2025-06-12 |
| 62541-0201-14 | 14 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (62541-2... | Qsymia | Vivus LLC | 2012-09-17 |
| 62541-0201-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (62541-2... | Qsymia | Vivus LLC | 2012-09-17 |
| 62541-0202-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (62541-2... | Qsymia | Vivus LLC | 2012-09-17 |
| 62541-0203-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62541-203-30) | Qsymia | Vivus LLC | 2012-09-17 |
| 62541-0204-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (62541-2... | Qsymia | Vivus LLC | 2012-09-17 |
| 66993-0780-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (66993-7... | phentermine and topiramate | Prasco Laboratories | 2025-06-01 |
| 66993-0781-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (66993-7... | phentermine and topiramate | Prasco Laboratories | 2025-06-01 |
| 66993-0782-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (66993-782-30) | phentermine and topiramate | Prasco Laboratories | 2025-06-01 |
| 66993-0783-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (66993-7... | phentermine and topiramate | Prasco Laboratories | 2025-06-01 |
Observed labelers:
Vivus LLC (5) ·
Dr.Reddys Laboratories Inc (4) ·
Prasco Laboratories (4) ·
Teva Pharmaceuticals, Inc. (4)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.